|1.||Farias, M: 1 article (09/2003)|
|2.||Yoshishige, D: 1 article (09/2003)|
|3.||Jackson, K: 1 article (09/2003)|
|4.||Caffrey, J L: 1 article (09/2003)|
|5.||Schultz, J E: 1 article (02/2001)|
|6.||Gross, G J: 1 article (02/2001)|
|7.||Husbands, S M: 1 article (09/2000)|
|8.||Coop, A: 1 article (09/2000)|
|9.||Woods, J H: 1 article (09/2000)|
|10.||Lewis, J W: 1 article (09/2000)|
09/01/2003 - "The delta1-selective antagonist 7-benzylidenenaltrexone (BNTX) reversed the vagal improvement with an ED50 near 1 x 10-21 mol/min, whereas the delta2-antagonist naltriben had no effect through 10-9 mol/min. Finally, the improved vagal bradycardia previously associated with nodal artery occlusion and endogenous MEAP was blocked by the selective delta1-antagonist BNTX. "
02/01/2001 - "In intact rat and rabbit hearts, nonselective opioid receptor antagonists such as naloxone and a selective delta1-opioid receptor antagonist, 7-benzylidenenaltrexone, have been shown to inhibit the cardioprotective effect of ischemic preconditioning, a phenomenon in which brief periods of ischemia protect the heart against a more prolonged period of ischemia. "
05/01/1995 - "Hypoxia-induced pial artery vasodilation was attenuated during moderate hypoxia (PaO2 approximately 35 mm Hg), while this response was blunted during severe hypoxia (PaO2 approximately 25 mm Hg), by the delta 1-opioid receptor antagonist 7-benzylidenenaltrexone (BNTX; 10(-8) M) (23 +/- 2 vs. 13 +/- 2 and 34 +/- 6 vs. 10 +/- 3% for moderate and severe hypoxia in the absence and presence of BNTX, respectively; n = 5). "
|2.||Opioid Receptors (Opioid Receptor)
|6.||tranilast (N 5')